Predictive significance of CYFRA21-1, squamous cell carcinoma antigen and carcinoembryonic antigen for lymph node metastasis in patients with esophageal squamous cancer

Mei, Xinyu; Zhu, Xiaoyan; Zuo, Li; Wu, Hanran; Guo, Mingzhou; Liu, Changqing

doi:10.1177/1724600819847999

Cited by 15 publications

(14 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High expression of Cyfra21-1 is an important factor affecting the survival of patients with advanced NSCLC (21). The preoperative serum Cyfra21-1 level was an independent predictor of lymph node metastasis in patients with esophageal squamous cancer (13). Rapid and quantitative detection of urinary Cyfra21-1 is a non-invasive approach for the diagnosis and prognosis of bladder cancer (14).…”

Section: Discussionmentioning

confidence: 99%

“…It has also been proven that Cyfra21-1 can independently be used as a prognostic indicator of a variety of malignant tumors. Numerous studies have shown that it has important prognostic significance for middle and advanced cancers, such as esophageal cancer, bladder cancer, epithelial ovarian cancer, and intrahepatic cholangiocarcinoma (13)(14)(15)(16). Lei et al found that Cyfra21-1 could be used to predict the early recurrence of OPSCC by comparing between groups, and the concentration of Cyfra21-1 was related to the clinicopathological stage of OPSCC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic significance of pre-treatment serum Cyfra21-1 as a tumor marker in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemoradiotherapy

Li¹,

Liu²,

Jin³

et al. 2020

Ann Transl Med

View full text Add to dashboard Cite

Background: Oropharyngeal squamous cell carcinoma (OPSCC) is a kind of squamous cell carcinoma of head and neck, and its incidence is on the rise in recent years. A variety of prognostic markers for OPSCC have been reported in many studies, but they are expensive or difficult to obtain. So, we retrospectively studied the prognostic significance of cytokeratin 19 soluble fragment (Cyfra21-1) in patients with OPSCC, in order to provide theoretical basis for accurate prognosis assessment. Methods: A retrospective analysis of the clinicopathological data of 85 OPSCC patients with concurrent radiotherapy and chemotherapy (CRT) admitted from January 2010 to June 2017. Serum Cyfra21-1 levels were measured before treatment. Analyze the relationship between Cyfra21-1 and clinical pathological characteristics of patients. The receiver operating characteristic (ROC) curve was used to calculate the cutoff value of Cyfra21-1. The Cox proportional hazard model was used to conduct univariate and multivariate analysis of related prognostic factors, and to determine the factors related to overall survival (OS) and progression-free survival (PFS).Results: The cutoff value for Cyfra21-1 was 2.93 ng/mL. The baseline data of patients in different Cyfra21-1 groups were balanced and comparable. In the univariate and multivariate analyses, it was found that Cyfra21-1 was associated with OS and PFS. A measurement of Cyfra21-1 ≥2.93 ng/mL indicated poor OS (P<0.001) and PFS (P=0.001). After adjusting for age and disease stage, Cyfra21-1 can independently affect the OS (HR =3.57, 95% CI: 1.60-7.99, P=0.002) and PFS (HR =2.89, 95% CI: 1.41-5.91, P=0.004) of patients with OPSCC treated with CRT.Conclusions: Pre-treatment Cyfra21-1 can be used as a prognostic marker for patients with OPSCC treated with CRT, which has important clinical significance.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prognostic significance of pre-treatment serum Cyfra21-1 as a tumor marker in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemoradiotherapy

Li¹,

Liu²,

Jin³

et al. 2020

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…In order to improve the early diagnosis and prolong the survival time for cancer patients, it is necessary to explore various sensitive tumor markers in cancers. Serum squamous cell carcinoma antigen (SCCA) is a commonly used clinical tumor marker for SCC, such as cervical SCC, head and neck SCC and ESCC [5][6][7]. To date, however, the prognostic role of SCCA in patients with ESCC remains controversial [8,9].…”

Section: Introductionmentioning

confidence: 99%

Development and validation a novel preoperative comprehensive prognostic score based on inflammatory and nutritional score, coagulation indicator and tumor marker in esophageal squamous cell carcinoma

Feng

Wang

Yang

et al. 2021

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

We herein propose a novel integrative score based on inflammatory and nutritional score, coagulation indicator and tumor marker, named comprehensive prognostic score (CPS), to predict postoperative survival in resectable esophageal squamous cell carcinoma (ESCC). We also aimed to establish and validate a nomogram based on CPS and other clinical features for individual survival prediction. A total of 490 resectable ESCC patients were randomly divided into either a training or validation cohort at a ratio of 7:3 for retrospective analysis. The CPS, based on squamous cell carcinoma antigen (SCCA), C-reactive protein to albumin ratio (CAR), neutrophil to lymphocyte ratio (NLR), and fibrinogen (FIB), was divided into two models to verify its prognostic value. The predictive model of CPS-based nomogram was established and validated in two cohorts. Patients with CPS low group in model 1 had better 5-year cancer-specific survival (CSS) than those in CPS high group (50.7% vs. 17.8%, P<0.001). For model 2, the 5-year CSS for CPS 0, 1 and 2 were 75.0%, 38.9% and 13.3%, respectively (P<0.001). CPS was confirmed as an independent prognostic score in both models. The CPS-based nomogram can accurately and effectively predict survival in resected ESCC. The CPS is a novel, simple, and effective predictor in resectable ESCC. Moreover, CPS has a potential independent prognostic value in predicting postoperative survival, which can accurately and effectively predict individual survival in resectable ESCC.

show abstract

“…CEA, cytokeratin 19 fragment 21‐1 (CYFRA21‐1), and squamous cell carcinoma antigen (SCC) were also evaluated for the diagnosis of ESCC. However, the sensitivity and specificity of these biomarkers are very limited in ESCC 8,9 …”

Section: Introductionmentioning

confidence: 99%

“…However, the sensitivity and specificity of these biomarkers are very limited in ESCC. 8,9 In the present study, we first used a ProcartaPlex Array to screen for serum proteins increased in 40 ESCC patients compared with the normal controls. By further verification of candidate serum markers with a larger sample of sera (174 ESCC patients and 189 normal controls), we found that serum eotaxin and IP-10 might be potential biomarkers in the diagnosis and therapeutic monitoring of ESCC patients.…”

Section: Introductionmentioning

confidence: 99%

Elevated serum eotaxin and IP‐10 levels as potential biomarkers for the detection of esophageal squamous cell carcinoma

Chang

Wang

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background and Aims Esophageal squamous cell cancer (ESCC) is one of the leading malignant cancers with a high incidence and mortality. Exploring novel serum biomarkers will help improve the management and monitoring of ESCC. Methods In the present study, we first used a ProcartaPlex Array to screen for serum proteins that were increased in 40 ESCC patients compared with matched normal controls; we found that eight proteins (IL‐2, IL‐5, IP‐10, IL‐8, eotaxin, TNF‐α, HGF, and MIP‐1b) had higher serum levels in ESCC patients than in normal controls. We further verified the clinical relevance of the candidate biomarkers with a larger sample of sera. Results In the 174 tested ESCC patients and 189 normal controls, the serum levels of eotaxin and IP‐10 were significantly higher in patients than in normal controls (p = 0.0038, 0.0031). In particular, these two proteins were also elevated in the sera of patients with early‐stage (0‐IIA) ESCC (p = 0.0041, 0.0412). When combining CEA and CYFRA21‐1 (in use clinically) with eotaxin or IP‐10, the effectiveness of detecting ESCC was superior to that of CEA and/or CYFRA21‐1 alone. Moreover, the serum level of eotaxin dropped significantly after surgical resection of primary tumors compared with that in preoperative ESCC samples (p < 0.001). Conclusions The data suggest that serum eotaxin and IP‐10 might be potential biomarkers for the detection of ESCC.

show abstract

Predictive significance of CYFRA21-1, squamous cell carcinoma antigen and carcinoembryonic antigen for lymph node metastasis in patients with esophageal squamous cancer

Cited by 15 publications

References 16 publications

Prognostic significance of pre-treatment serum Cyfra21-1 as a tumor marker in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemoradiotherapy

Prognostic significance of pre-treatment serum Cyfra21-1 as a tumor marker in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemoradiotherapy

Development and validation a novel preoperative comprehensive prognostic score based on inflammatory and nutritional score, coagulation indicator and tumor marker in esophageal squamous cell carcinoma

Elevated serum eotaxin and IP‐10 levels as potential biomarkers for the detection of esophageal squamous cell carcinoma

Contact Info

Product

Resources

About